FindTrial
Sign In

Questionnaire study

OTHER7 trials

Sponsors

University of Gaziantep, Istanbul Bilgi University, Hacettepe University, Aysima Barlak

Conditions

Back PainChronic DiseaseChronic Kidney Disease Requiring Chronic DialysisChronic Kidney Disease(CKD)EducationFamilial Mediterranean Fever (FMF )FibromyalgiaKidney Transplantation

Unknown Phase

Determination of Physical Activity Status and Adherence to the Mediterranean Diet in Adults and Related Health Outcomes
CompletedNCT05001256
University of GaziantepChronic Disease, Mediterranean Diet, Nutrition +2
Start: 2021-07-15End: 2021-09-10Updated: 2021-10-20
Turkish Validity and Reliability of Physiotherapist Self-Efficacy Questionnaire
CompletedNCT05335291
Istanbul Bilgi UniversityEducation, Physiotherapy, Self Efficacy
Start: 2022-04-06End: 2022-11-03Updated: 2022-11-04
Investigation of the Validity, Reliability, and Responsiveness of BETY-BQ in Chronic Kidney Disease, on Dialysis, and Kidney Transplantation
RecruitingNCT06591702
Hacettepe UniversityChronic Kidney Disease(CKD), Chronic Kidney Disease Requiring Chronic Dialysis, Kidney Transplantation
Start: 2024-02-21End: 2026-12-31Target: 150Updated: 2024-09-19
Investigation of the Validity, Reliability, and Responsiveness of the BETY-BQ in Myositis
RecruitingNCT06587724
Hacettepe UniversityMyositis
Start: 2024-07-24End: 2026-12-31Target: 100Updated: 2024-09-19
Investigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the CAP Questionnaire
RecruitingNCT06825650
Hacettepe UniversityBack Pain, Fibromyalgia, Osteoarthritis
Start: 2024-11-28End: 2027-11-28Target: 300Updated: 2025-02-13
Investigation of the Validity, Reliability and Responsiveness of the BETY-BQ in FMF
Not yet recruitingNCT06830213
Aysima BarlakFamilial Mediterranean Fever (FMF )
Start: 2025-02-18End: 2027-12-30Target: 100Updated: 2025-02-19
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
RecruitingNCT07182968
Hacettepe UniversityPatient Perspective, Scleroderma (Limited and Diffuse), Systemic Sclerosis (Scleroderma) +1
Start: 2025-08-04End: 2027-08-04Target: 50Updated: 2025-09-19